Holen Sie sich die Stockscreener-App
0.459
2.28%
-0.0107
Handel nachbörslich:
.46
0.001
+0.22%
Schlusskurs vom Vortag:
$0.4697
Offen:
$0.46
24-Stunden-Volumen:
610.52K
Relative Volume:
1.28
Marktkapitalisierung:
$39.49M
Einnahmen:
$2.24M
Nettoeinkommen (Verlust:
$-136.67M
KGV:
-0.2004
EPS:
-2.29
Netto-Cashflow:
$-102.08M
1W Leistung:
-16.30%
1M Leistung:
-25.23%
6M Leistung:
-69.60%
1J Leistung:
-87.59%
1-Tages-Spanne:
$0.421
$0.4844
1-Wochen-Bereich:
$0.421
$0.5583
52-Wochen-Spanne:
$0.421
$4.4278
Century Therapeutics Inc Stock (IPSC) Company Profile
Firmenname
Century Therapeutics Inc
Sektor
Branche
Telefon
215-981-4000
Adresse
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Vergleichen Sie IPSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.459 | 39.49M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-05-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-12 | Eingeleitet | William Blair | Mkt Perform |
| 2021-07-13 | Eingeleitet | BofA Securities | Buy |
| 2021-07-13 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-13 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
H.C. Wainwright cuts Century Therapeutics target to $2 By Investing.com - Investing.com UK
American Century Companies Inc. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Guggenheim Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
What is Chardan Capital’s Estimate for IPSC FY2025 Earnings? - Defense World
Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Century Therapeutics (NASDAQ:IPSC) Price Target Lowered to $7.00 at Chardan Capital - Defense World
William Blair Issues Optimistic Forecast for IPSC Earnings - The AM Reporter
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Q1 EPS Estimate for Century Therapeutics Boosted by Analyst - Defense World
Chardan Cuts Price Target on Century Therapeutics to $7 From $11, Keeps Buy Rating - MarketScreener
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results - MSN
Guggenheim Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 - Defense World
Piper Sandler Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $2.00 - Defense World
Guggenheim cuts Century Therapeutics target to $5, keeps Buy rating By Investing.com - Investing.com Canada
What is William Blair’s Estimate for IPSC Q3 Earnings? - Defense World
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Century Therapeutics Reports 2024 Financial Results and Strategic Updates - TipRanks
Leerink Partners Adjusts Price Target on Century Therapeutics to $8 From $13, Keeps Outperform Rating - Marketscreener.com
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Century Therapeutics, Inc. SEC 10-K Report - TradingView
Century Therapeutics Announces Pipeline Re-Prioritization to Focus on Transformational Programs and Extends Cash Runway into Q4 2026 - Nasdaq
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Century Therapeutics Secures 2-Year Cash Runway with $220M War Chest - StockTitan
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - Defense World
Century therapeutics officer sells shares worth $1,451 By Investing.com - Investing.com South Africa
Century Therapeutics SVP sells $762 in stock By Investing.com - Investing.com South Africa
Century therapeutics CEO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Century therapeutics CEO sells shares to cover tax obligations - Investing.com
Century Therapeutics COO Farid Adrienne sells $1,450 in stock - Investing.com India
Century therapeutics officer sells shares worth $1,451 - Investing.com
Century Therapeutics SVP sells $762 in stock - Investing.com
Century Therapeutics COO Farid Adrienne sells $1,450 in stock By Investing.com - Investing.com UK
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Century Therapeutics (IPSC) Expected to Announce Quarterly Earnings on Thursday - Defense World
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.
Century Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Century Therapeutics faces Nasdaq delisting over share price - Investing.com India
Century Therapeutics Receives Nasdaq Notice For Bid Price Deficiency -February 28, 2025 at 04:20 pm EST - Marketscreener.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Century Therapeutics CEO sells shares worth $27,179 - Investing.com
Century Therapeutics CEO sells shares worth $27,179 By Investing.com - Investing.com UK
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MSN
Finanzdaten der Century Therapeutics Inc-Aktie (IPSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):